BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 11469270)

  • 1. Safety of drugs commonly used to treat hypertension, dyslipidemia, and Type 2 diabetes (the metabolic syndrome): part 2.
    Marcus AO
    Diabetes Technol Ther; 2000; 2(2):275-81. PubMed ID: 11469270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of oral anti-diabetic agents in modifying cardiovascular risk factors.
    Shin JJ; Rothman J; Farag A; McFarlane SI; Sowers JR
    Minerva Med; 2003 Dec; 94(6):401-8. PubMed ID: 14976468
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacological regulation of blood glucose levels in non-insulin-dependent diabetes mellitus.
    Bressler R; Johnson DG
    Arch Intern Med; 1997 Apr; 157(8):836-48. PubMed ID: 9129543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Diabetes Prevention Program.
    Muniyappa R; El-Atat F; Aneja A; McFarlane SI
    Curr Diab Rep; 2003 Jun; 3(3):221-2. PubMed ID: 12762969
    [No Abstract]   [Full Text] [Related]  

  • 5. The use of insulin alone and in combination with oral agents in type 2 diabetes.
    Buse JB
    Prim Care; 1999 Dec; 26(4):931-50. PubMed ID: 10523468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Combination therapy with biguanides].
    Sakura H
    Nihon Rinsho; 2002 Oct; 60 Suppl 10():724-8. PubMed ID: 12430309
    [No Abstract]   [Full Text] [Related]  

  • 7. Pharmacologic management of diabetes mellitus.
    Mozersky RP
    J Am Osteopath Assoc; 1999 Dec; 99(12 Suppl):S15-9. PubMed ID: 10659525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Using dose-response characteristics of therapeutics agents for treatment decisions in type 2 diabetes.
    Garber AJ
    Diabetes Obes Metab; 2000 Jun; 2(3):139-47. PubMed ID: 11220549
    [No Abstract]   [Full Text] [Related]  

  • 9. Insulin as a first-line therapy in type 2 diabetes: should the use of sulfonylureas be halted?
    Standl E; Schnell O
    Diabetes Care; 2008 Feb; 31 Suppl 2():S136-9. PubMed ID: 18227474
    [No Abstract]   [Full Text] [Related]  

  • 10. Clinical efficacy of metformin against insulin resistance parameters: sinking the iceberg.
    Zimmet P; Collier G
    Drugs; 1999; 58 Suppl 1():21-8; discussion 75-82. PubMed ID: 10576521
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of insulin secretagogues in the treatment of type 2 diabetes.
    Luna B; Hughes AT; Feinglos MN
    Prim Care; 1999 Dec; 26(4):895-915. PubMed ID: 10523467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The role of troglitazone in treating the insulin resistance syndrome.
    Granberry MC; Schneider EF; Fonseca VA
    Pharmacotherapy; 1998; 18(5):973-87. PubMed ID: 9758309
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Anti-diabetic treatment, insulin resistance and cardiovascular disease in patients with type 2 diabetes].
    Hemmingsen B; Lund SS; Vaag A
    Ugeskr Laeger; 2009 May; 171(19):1598-602. PubMed ID: 19419642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New oral therapies for type 2 diabetes mellitus: The glitazones or insulin sensitizers.
    Mudaliar S; Henry RR
    Annu Rev Med; 2001; 52():239-57. PubMed ID: 11160777
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Is there evidence that oral hypoglycemic agents reduce cardiovascular morbidity/mortality? Yes.
    Bianchi C; Miccoli R; Daniele G; Penno G; Del Prato S
    Diabetes Care; 2009 Nov; 32 Suppl 2(Suppl 2):S342-8. PubMed ID: 19875578
    [No Abstract]   [Full Text] [Related]  

  • 16. Pharmacotherapy of diabetes mellitus: implications for the prevention and treatment of cardiovascular disease.
    Ragucci E; Zonszein J; Frishman WH
    Heart Dis; 2003; 5(1):18-33. PubMed ID: 12549986
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drugs for diabetes.
    Abramowicz M; Zuccotti G;
    Treat Guidel Med Lett; 2005 Aug; 3(36):57-62. PubMed ID: 16012392
    [No Abstract]   [Full Text] [Related]  

  • 18. Managing type 2 diabetes. A look at the newer agents.
    Larmore SS
    JAAPA; 1999 Jun; 12(6):47-8, 51-4, 57. PubMed ID: 10728087
    [No Abstract]   [Full Text] [Related]  

  • 19. [Cardiovascular effects of the thiazolidinedione troglitazone].
    Yamada K; Kuzuya H; Nakano T
    Nihon Rinsho; 2000 Feb; 58(2):435-9. PubMed ID: 10707572
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New directions in type 2 diabetes mellitus: an update of current oral antidiabetic therapy.
    Brown DL; Brillon D
    J Natl Med Assoc; 1999 Jul; 91(7):389-95. PubMed ID: 10643211
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.